Golimumab

Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.

Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...